Index

acceptance criteria 22–3
assay development 22–3
Cylex technology 204–7
enzyme-linked immunospot assays 142–3, 170, 187–9
ex vivo stimulation assays 46
flow cytometry 100–1
neutralization bioassays 235–6
peripheral blood mononuclear cells 34
accountability cytometry 111
accuracy 138–9
acid citrate dextrose (ACD) 241–2
acquired immunodeficiency syndrome see HIV/AIDS
actinomycin D-mannitol 212, 218–19
activation markers 74–5
ADAs see anti-drug antibodies (ADAs)
adenosine triphosphate (ATP) 194, 195–7, 205–6
annexin V 79
antibody-coated plates 168, 187
anticoagulants
  endpoint assays 241–2
  ex vivo stimulation assays 40–1, 43
flow cytometry 76
peripheral blood mononuclear cells 30–1, 32
anti-drug antibodies (ADAs) 209–10
antigen presenting cells (APCs) 140
antigen-specific T cell assays 12, 26–7
APCs see antigen presenting cells (APCs)
apoptosis 76, 79–81
assay controls
  definition 27
  ex vivo stimulation assays 40
  neutralization bioassays 211, 215, 217, 222, 235
assay format 3
ATP see adenosine triphosphate (ATP)
automated screening assays 278
binding antibodies 258–9
biotin labeling 51, 60
B-lymphocytes 193–4
calibration curves 205
capture antibody-coated plates 168, 187
CBA see cytokine bead arrays (CBA)
CD3 78, 88–92, 95–100
INDEX

CD4
- Cylex technology 194–6, 201–2, 205–6
- flow cytometry 78
- good laboratory practice 279
- HIV/AIDS 240, 247–52, 255, 267
- immunohistochemistry 69

CD8
- flow cytometry 78
- good laboratory practice 279
- HIV/AIDS 240, 248, 250–2, 255, 267

CD19 78, 194–6, 198–9, 201, 205–6

CD25 74–5, 86, 93, 95–7, 100–3

CD31 50

CD45 75, 78

CD69 74–5

CEF peptides 134, 137

cell banking 2–3

cell cycle analysis 78–9

cell density 29, 153, 154–5, 160, 177–9

cell passage number 233

CFSE labeled proteins 255

chemokine receptors (CKR) 75

circulating tumor cells (CTCs) 12

CKR see chemokine receptors (CKR)

CLA see cutaneous lymphocyte antigen (CLA)

coefficient of variation, definition 13

combinatorial chemistry 277–8

consistency controls 211–12, 215, 217, 219–21

control analytes 12

control stability 17–18

CPA see cytokine protein arrays (CPA)

critical reagents 3, 19, 218–19, 234

Crohn’s disease 58

cryopreservation see freeze/thaw procedures

CTCs see circulating tumor cells (CTCs)

culture time 177, 234

cutaneous lymphocyte antigen (CLA) 86, 88–95, 96–103

cut-off
- assay development 7, 23
- neutralization bioassays 213–14, 215, 231–2

Cylex technology
- acceptance criteria 204–7
- assay plates 199
- calibration curves 205

data handling 197

drug interference 203, 205

lymphocyte activation capacity 193–207

methodology 195–7

optimization 197–8

precision 199–203, 204

reagents 195–7, 199

sample handling 195, 198–200, 206–7

specificity 203, 205

stability 197–9

standard curves 197

variability 199–203, 204

cytokine bead arrays (CBA) 130–2

cytokine protein arrays (CPA) 130–2

cytokine release models 38–9

cytokine storms 279

cytotoxic T lymphocytes (CTLs) 250, 252

data handling
- assay development 22
- Cylex technology 197
- definitions 12
- enzyme-linked immunospot assays 151–2, 187–9
- ex vivo stimulation assays 46
- flow cytometry 78–9, 111, 118–19, 121
- immunohistochemistry assays 65–7, 68
- peripheral blood mononuclear cells 34
dilutional linearity 225
diurnal variations 42
dose response curves 227–30

drug interference
- Cylex technology 203, 205
- neutralization bioassays 216–17, 232
dUTPase 50, 61

early activation markers 74–5

EDTA plasma 213–14, 241–2

ELISA see enzyme-linked immunosorbent assays (ELISA)

ELISPOT see enzyme-linked immunospot (ELISPOT) assays

endpoint assays
- anticoagulants 241–2
- binding antibodies 258–9
clinical trials 248–50
enzyme-linked immunosorbent assays 243–4, 249
enzyme-linked immunospot assays 252–5
freeze/thaw procedures 242
good laboratory practice 262–7
HIV/AIDS 239–75
humoral immune responses to HIV 258–62
internal/external audits 265
laboratory programs 241–8, 262–3
methodology 246–8
neutralizing antibodies 259–62
nucleic acid tests 243, 245, 249
peptide antigen selection 257–8
personnel training 263
polychromatic flow cytometry 255–7
quality assurance 265–7
quality control 244
reagents/equipment 264
reporting requirements 264–5
safety testing 243
sample handling 242
specimen processing 241–2
standard operating procedures 263–6
T cell immunogenicity 251–8
vaccine pipeline 248–50
variability 262, 264
Western blot analyzes 243, 244–6, 247–9
enzyme-linked immunosorbent assays (ELISA)
anti-drug antibodies 210
cytokines 130–2
drug development 243–8, 249
ex vivo stimulation assays 39, 42, 45
HIV/AIDS 243–6, 249
interferon 223–7, 235
intercellular cytokine staining 111
optimization 134, 135
reagents 150–1
regulatory bodies 129
enzyme-linked immunospot (ELISPOT) assays
acceptance criteria 142–3, 170, 187–9
accuracy 138–9
assay development 12
assay plates 167–8, 185–7
cell density 153, 154–5, 160, 177–9
cross-titration 134, 136
culture time 177
data handling 151–2, 187–9
drug development 252–5
good laboratory practice 128, 266–7
HIV/AIDS 252–5
IL-5 ELISPOT assays 173–91
interferon-γ 131, 137, 143–4, 147–72, 173, 190, 252–3
interleukins 173–4, 175
intracellular cytokine staining 108, 111, 132, 133
limits of detection/quantification 140–1, 155, 160, 168–9, 187–9
linearity 140
lymphotcyte activation capacity 194
methodology 149–52, 174–5
multimerized MHC molecules 133
optimization 134–8, 176–8
overview 129–30
parameter testing 138
performance comparisons 130–3
peripheral blood mononuclear cells 29, 133–4, 139, 148–70, 174–87, 189–90
polyclonal activators 148, 150, 153–70
precision 139, 163–6, 182–5, 190
 protocols 150–1, 169–70
qualification experiments 138, 142
range 141
reagents 150–1, 152–4, 166–70, 175–6, 185–7
reference samples 127–46
regulatory bodies 127–9, 144
specificity 139–40, 152–4, 175–6, 190
stability 162–3, 168, 178, 181
statistics 143–4
validation controls 152–66
variability 134–8, 142, 161–2, 163–6, 182–5, 190
viability assessments 180–1
EQA see external quality assurance (EQA)
**INDEX**

*ex vivo* stimulation assays 46
acceptance criteria 46
anticoagulants 40–1, 43
assay development 40–3
clinical testing of samples 46
conditions 41
cytokine release models 38–9
data handling 46
definitions 39–40
diurnal variations 42
freeze/thaw procedures 38
limits of quantification 45
optimization 40–3
precision 44–5
robustness 43–4
sample handling 40–1, 42–3
specificity/interference 41
stability 42–4
validation controls 39–40, 41–2
variability 44–5
whole blood 37–47
external audits 265
external quality assurance (EQA) 266–7

FACS see fluorescence-activated cell-sorting (FACS)
FFPE see formalin-fixed, paraffin-embedded (FFPE) tissues
FITC see fluorescein isothiocyanate (FITC)
fit-for-purpose validation 279–80
flow cytometry
acceptance criteria 100–1
accountability 111
anticoagulants 76
apoptosis 76, 79–81
applications 73–81
certification 110
checklist 114
data handling 78–9, 111, 118–19, 121
endpoint assays 255–7
good laboratory practice 107–13, 116, 124
immunophenotyping 74–5
implementation 101–2
instrumentation 87, 101, 103, 109–10, 120, 122–4
intersubject range of marker expression 91, 103
intracellular cytokine staining 80, 107–25
in vitro stimulation 117
labeling and staining 77, 78–9, 86–7, 89
limits of quantification 122–3
lymphocyte activation capacity 194
lyophilization 115–16
methodology 119–22
multimerized MHC molecules 133
phospho-specific 80–1
precision 98–100, 103, 108
reagents 87–91, 103, 110, 113–15, 122–3
regulatory bodies 129
sample handling 76–7, 91–8, 110–2, 121
specificity 77, 87–91
stability 76–7, 91–8, 103
staining 112, 117–18, 121
standardization 108–13, 123–4
T-cell surface markers 85–105
validation controls 116–22
variability 91, 96, 99–100, 103, 111–12
whole blood 76–7, 85–105
fluorescin isothiocyanate (FITC) 51, 60
fluorescence-activated cell-sorting (FACS) 129, 131
formalin-fixed, paraffin-embedded (FFPE) tissues 51, 54, 55–6, 59, 61–2
four-layered assays 4
freeze/thaw procedures
endpoint assays 242
enzyme-linked immunospot assays 149–50, 154–66, 178–82
ex vivo stimulation assays 38
neutralization bioassays 220–1, 231, 234
peripheral blood mononuclear cells 26–7, 29

GCP see good clinical practice (GCP)
genomics 277–8
GLP see good laboratory practice (GLP)
good clinical practice (GCP) 263

assay development 2, 9
endpoint assays 262–7
enzyme-linked immunospot assays 128
flow cytometry 102–3, 107–13, 116, 124
future directions 277–80
immunohistochemistry assays 53–6, 66
internal/external audits 265
laboratory programs 262–3
personnel training 263
quality assurance 265–7
reagents/equipment 264
reporting requirements 264–5
see also standard operating procedures

heat-induced epitope retrieval (HIER) 59
heparinized plasma 213–14
HER2 50, 52, 63, 69
Herceptin 52–3, 69
HIER see heat-induced epitope retrieval (HIER)
high throughput screening (HTS) 278
HIV SELECTEST 246, 249
HIV/AIDS
Cylex technology 194
endpoint assays 239–75
flow cytometry 74, 108
humoral immune responses to HIV 1, 258–62
HVTN see HIV-1 vaccine trials network
ICS see intracellular cytokine staining (ICS)
IHC see immunohistochemistry (IHC) assays
IL-5 ELISPOT assays 173–91
immune function assays 249
immunohistochemistry (IHC) assays 49–72
antibodies 49–51, 57, 59, 61
applications 68–72
assay development 57–65, 68
biomarker scoring 62–4, 67, 69
clinical studies 66–72
data handling 67
detection systems 60
fixation 51, 54, 55, 57, 59, 61–2
good laboratory practice 53–6, 66
labeling and staining 51–2, 54, 59–60, 62–3, 66, 71
overview 49–53
quality control 65–6
quantitative data 64–5
rational image analysis 64–5
sample handling 55–6
sensitivity 61
specificity 60, 61–2
testing parameters 58, 66
tissue selection 58–9
validation controls 60
immunophenotyping 74–5
interferon-γ
enzyme-linked immunospot assays 131, 137–8, 143–4, 147–72, 173, 190, 252–3
flow cytometry 108, 122–5
neutralization bioassays 210, 221–36
interleukins
enzyme-linked immunospot assays 147–9
flow cytometry 85–6, 88–91, 93–4, 96–102
IL-5 ELISPOT assays 173–91
neutralization bioassays 210, 215, 221–2, 225, 227–8
internal audits 265
intersubject range of marker expression 91, 103
intracellular cytokine staining (ICS) 132, 133
enzyme-linked immunospot assays 141, 155, 160, 168–9, 187–9
flow cytometry 80, 107–25
HIV/AIDS 252, 255–6, 266–7
Ki 67, 68
late activation markers 74–5
lead in to assay development 2–3
limits of detection (LOD) 17, 140–1
limits of quantification (LOQ)
  assay development 7, 17, 33
  enzyme-linked immunospot assays 141, 155, 160
  ex vivo stimulation assays 45
  flow cytometry 122–3
  neutralization bioassays 223–5
linearity 123, 140, 225
lipopolysaccharide (LPS) 195–6, 201–2
LOD see limits of detection (LOD)
LOQ see limits of quantification (LOQ)
lymphoproliferative assays (LPA) 252
lyophilization 115–16
MAB see monoclonal antibodies (MAB)
major histocompatibility complex (MHC) 278–9
master banks 2–3
matrix effects
  assay development 14–15, 20–1
  neutralization bioassays 226, 230–1
mean, definition 13
MHC see major histocompatibility complex (MHC)
microarrays 278
monoclonal antibodies (MAB) 4, 115, 119
MS see multiple sclerosis (MS)
multi-layered assays 4
multimerized MHC molecules 133
multiple sclerosis (MS) 174
multiplex analysis 39, 42
NAbs see neutralizing antibodies (Nabs)
NAT see nucleic acid tests (NAT)
natural killer (NK) cells 210, 221–2
neutral buffered formalin (NBF) 51, 54, 55
neutralization bioassays 209–37
acceptance criteria 235–6
anti-drug antibodies 209–10
cell passage number 233
clinical samples 236
critical reagents 218–19, 234
culture time 234
cut-off 213–14, 215, 231–2
cytokine interference 225
dilutional linearity 225
dose response curves 227–30
drug interference 216–17, 232
enzyme-linked immunoassay 210, 223–7, 235
freeze/thaw procedures 220–1, 231, 234
HIV/AIDS 259–62
induction assays 227–33
interferon-γ 210, 221–36
limits of quantification 223–5
matrix effects 226, 230–1
methodology 212–13, 222–3
precision 226, 232–3
quality control 227, 235
robustness 217, 233–5
ruggedness 217
sample handling 212, 215, 219–21
sensitivity 214–15, 232
specificity 215–17, 231
stability 219–21, 226, 234–5
standard curves 223–5
tumor necrosis factor 210, 211–21, 225
validation controls 211–12, 215, 217, 219–22, 228–31, 235
variability 217–19, 226, 232–3
neutralizing antibodies (NAbs)
  assay development 2, 4–5
  endpoint assays 259–62
  neutralization bioassays 210, 215, 221, 222–3, 227–36
NHS see normal human serum (NHS)
NIAID–CANVAC study 108
NK see natural killer (NK) cells
normal human serum (NHS) 212–14, 231
nucleic acid tests (NAT) 243, 245, 249
one-layered assays 4
optimal conditions 27, 40
optimization 13–15
  Cylex technology 197–8
  enzyme-linked immunospot assays 134–8, 176–8
  ex vivo stimulation assays 40–3
  peripheral blood mononuclear cells 28–31

p24 gag 260–2
p53 50
PAbs see polyclonal antibodies (PAbs)
PBLs see peripheral blood lymphocytes (PBLs)
PBMCs see peripheral blood mononuclear cells (PBMCs)
PBS see phosphate buffered saline (PBS)
pentamer analysis 133
perforin (PFN) 137
peripheral blood lymphocytes (PBLs) 88–90
peripheral blood mononuclear cells (PBMCs)
  acceptance criteria 34
  anticoagulants 30–1, 32
  antigen-specific T cell immunity assays 26–7
  assay development 28–31
  cell density 29
  clinical studies 35
  conditions 30
  data handling 34
  definitions 27–8
  endpoint assays 241–2, 252, 254, 256, 259
  enzyme-linked immunospot assays 29, 133–4, 139, 148–70, 174–87, 189–90
  flow cytometry 80, 108, 116–17, 122
  freeze/thaw procedures 26–7, 29
  isolation 28–9
  limits of quantification 33
  optimization 28–31
  robustness 33
  sample handling 32
  specificity/interference 30
  stability 31, 32
validation controls 27, 31
variability 32–3
PFN see perforin (PFN)
PHA-P see phytohemagglutinin-P (PHA-P)
phosphate buffered saline (PBS) 51
phospho-specific flow cytometry 80–1
phytohemagglutinin-P (PHA-P)
  Cylex technology 195–6, 197–8, 200, 205
  IFN-γ ELISPOT assays 148, 150, 153–70
  IL-5 ELISPOT assays 175–6, 189
PMA–ionomycin
  IFN-γ ELISPOT assays 148, 150, 168–70
  IL-5 ELISPOT assays 175–87, 189
polychromatic flow cytometry 255–7
polyclonal antibodies (PAbs) 230, 232–3
precision
  assay development 7, 16, 21–2
  Cylex technology 199–203, 204
  enzyme-linked immunospot assays 139, 163–6, 182–5, 190
  ex vivo stimulation assays 44–5
  flow cytometry 98–100, 103, 108
  neutralization bioassays 226, 232–3
  see also variability
predose controls 27, 40
proliferation assays
  assay development 2, 3
  lymphocyte activation capacity 194
psoriasis 69–70, 86
PSVs see pseudoviruses
quadrant markers 78
qualification experiments 138, 142
 qualitative data, definition 13
quality assurance 109–11, 128, 265–7
quality control
  endpoint assays 243–4
  enzyme-linked immunospot assays 128, 151, 153
immunohistochemistry assays 65–6
neutralization bioassays 227, 235
samples 39
quantitative data
  definition 12
  immunohistochemistry assays 64–5
  see also limits of quantification
range 141
rational image analysis 64–5
reference samples 127–46
relative standard deviation (RSD) 143–4
reporting requirements 264–5
reproducibility see variability
robustness
  assay development 8
  ex vivo stimulation assays 43–4
  neutralization bioassays 217, 233–5
  peripheral blood mononuclear cells 33
RSD see relative standard deviation
ruggedness 217
safety testing 243
sample analytes 12
sample handling
  assay development 5, 17–19
  Cylex technology 195, 198–200, 206–7
  endpoint assays 242
  enzyme-linked immunospot assays 149–50, 152–66, 178–82
  ex vivo stimulation assays 40–1, 42–3
  flow cytometry 76–7, 91–8, 110–2, 121
  immunohistochemistry assays 55–6
  neutralization bioassays 212, 215, 219–21
  peripheral blood mononuclear cells 32
  see also stability
sample matrices
  assay development 14–15, 20–1
  neutralization bioassays 226, 230–1
  sample specific controls 212, 215, 217, 222, 231
SDS-PAGE see sodium dodecyl sulfate poly-acrylamide gel (SDS-PAGE)
SEA/SEB see staphylococcal enterotoxins (SEA/SEB)
SELECTEST 246, 249
selectivity 7–8
semi-quantitative data
  definition 12
  immunohistochemistry assays 64–5
sensitivity
  immunohistochemistry assays 61
  neutralization bioassays 214–15, 232
sodium dodecyl sulfate poly-acrylamide gel (SDS-PAGE) 244
sodium heparin 241–2
SOPs see standard operating procedures
specificity
  assay development 7–8, 16, 19–21
  Cylex technology 203, 205
  enzyme-linked immunospot assays 139–40, 152–4, 175–6, 190
  ex vivo stimulation assays 41
  flow cytometry 77, 87–91
  immunohistochemistry assays 60, 61–2
  neutralization bioassays 215–17, 231
  peripheral blood mononuclear cells 30
stability
  assay development 8, 15–19
  Cylex technology 197–9
  enzyme-linked immunospot assays 162–3, 168, 178, 181
  ex vivo stimulation assays 42–4
  flow cytometry 76–7, 91–8, 103
  neutralization bioassays 219–21, 226, 234–5
  peripheral blood mononuclear cells 31, 32
standard curves
  assay development 3
  Cylex technology 197
  neutralization bioassays 223–5
  performance 15–17, 23
standard deviation, definitions 13, 143–4
standard operating procedures (SOPs)
  assay development 22
  Cylex technology 197
  endpoint assays 263–6
  enzyme-linked immunospot assays 128
  flow cytometry 109
  immunohistochemistry assays 52, 55–6, 62, 65–7
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staphylococcal enterotoxins (SEA/SEB)</td>
<td>195–6, 201–2</td>
</tr>
<tr>
<td>Cylex technology</td>
<td>195–6, 201–2</td>
</tr>
<tr>
<td>enzyme-linked immunospot assays</td>
<td>148, 169–70, 175</td>
</tr>
<tr>
<td>targeted drug therapy</td>
<td>69, 71</td>
</tr>
<tr>
<td>tetramer analysis</td>
<td>133, 252–3</td>
</tr>
<tr>
<td>T-lymphocytes</td>
<td></td>
</tr>
<tr>
<td>Cylex technology</td>
<td>193–4</td>
</tr>
<tr>
<td>endpoint assays</td>
<td>251–8</td>
</tr>
<tr>
<td>enzyme-linked immunospot assays</td>
<td>129, 133, 147–9, 173–4</td>
</tr>
<tr>
<td>flow cytometry</td>
<td>74–5, 85–105</td>
</tr>
<tr>
<td>good laboratory practice</td>
<td>278–9</td>
</tr>
<tr>
<td>tumor necrosis factor (TNF)</td>
<td>210, 211–21, 225</td>
</tr>
<tr>
<td>TUNEL assays</td>
<td>79</td>
</tr>
<tr>
<td>two-layered assays</td>
<td>4</td>
</tr>
<tr>
<td>vaccine pipeline</td>
<td>248–50</td>
</tr>
<tr>
<td>validation controls</td>
<td>6–8</td>
</tr>
<tr>
<td>assay development</td>
<td>13, 15–16, 20</td>
</tr>
<tr>
<td>enzyme-linked immunospot assays</td>
<td>152–66</td>
</tr>
<tr>
<td>ex vivo stimulation assays</td>
<td>39–40, 41–2</td>
</tr>
<tr>
<td>flow cytometry</td>
<td>116–22</td>
</tr>
<tr>
<td>immunohistochemistry assays</td>
<td>60</td>
</tr>
<tr>
<td>neutralization bioassays</td>
<td>211–12, 215, 217, 219–22, 228–31, 235</td>
</tr>
<tr>
<td>peripheral blood mononuclear cells</td>
<td>27, 31</td>
</tr>
<tr>
<td>validation plans</td>
<td>5–8</td>
</tr>
<tr>
<td>validation reports</td>
<td>8, 14, 16</td>
</tr>
<tr>
<td>variability</td>
<td></td>
</tr>
<tr>
<td>assay development</td>
<td>21–2</td>
</tr>
<tr>
<td>Cylex technology</td>
<td>199–203, 204</td>
</tr>
<tr>
<td>endpoint assays</td>
<td>262, 264</td>
</tr>
<tr>
<td>enzyme-linked immunospot assays</td>
<td>134–8, 142, 161–2, 163–6, 182–5, 190</td>
</tr>
<tr>
<td>ex vivo stimulation assays</td>
<td>44–5</td>
</tr>
<tr>
<td>flow cytometry</td>
<td>91, 96, 98–100, 103, 111–12</td>
</tr>
<tr>
<td>neutralization bioassays</td>
<td>217–19, 226, 232–3</td>
</tr>
<tr>
<td>peripheral blood mononuclear cells</td>
<td>32–3</td>
</tr>
<tr>
<td>viability</td>
<td>180–1</td>
</tr>
<tr>
<td>Western blot analyzes</td>
<td>243, 244–6, 247–9</td>
</tr>
<tr>
<td>whole blood (WB)</td>
<td></td>
</tr>
<tr>
<td>ex vivo stimulation assays</td>
<td>37–47</td>
</tr>
<tr>
<td>flow cytometry</td>
<td>76–7, 85–105</td>
</tr>
</tbody>
</table>